Manzamine A

Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1^[1][2][3][4]. In Vitro: Manzamine A (5-50 µM, 18 h) decreases tau phosphorylation, measured with ELISA^[1].
Manzamine A (10 µM) inhibits yeast S. cerevisiae growth by 30%^[2].
Manzamine A displays a few enlarged vacuoles in yeast^[2].
Manzamine A (2.5-10 µM, 24 h) increases acidity in pancreatic cancer cells and non-malignant Vero cells^[2].
Manzamine A (1 µM, 24 h) inhibits HSV-1 infection in SIRC cells^[4].
Manzamine A shows antimalarial activity with an IC₅₀ of 8.0 nM (D6 clone) and 11 nM (W2 clone)^[5].
In Vivo: Manzamine A (50 and 100 mol/kg, p.o. or i.p.) inhibits the growth of the rodent malaria parasite Plasmodium berghei in infected mice^[6].
Manzamine A (8 mg/kg, i.p., daily for 8 consecutive days) prolongs the survival of SW mice to 20 days^[7].